GlassScriptPhysician profile
Thomas K Tsao
NPI 1659343556
$2,982.33
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $618 · 2021: $879 · 2022: $531.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $456.98 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $438.18 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $410.85 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $343.15 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $255.95 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $190.44 | 2021 | |
| Novartis Pharmaceuticals Corporation | $103.52 | 2019-2020 | |
| Allergan, INC. | $97.28 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $95.97 | 2019-2022 | |
| Corium, LLC | $89.49 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.61 | 2021-2022 | |
| Shire North American Group INC | $68.13 | 2019 | |
| Tris Pharma INC | $57.40 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $50.85 | 2019-2020 | |
| Almatica Pharma LLC | $43.85 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $34.43 | 2022 | |
| Jazz Pharmaceuticals INC. | $33.41 | 2021 | |
| Vanda Pharmaceuticals INC. | $27.29 | 2019-2020 | |
| Adlon Therapeutics L.P. | $25.39 | 2020-2021 | |
| Alkermes, INC. | $24.82 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.15 | 2019 | |
| Eisai INC. | $15.09 | 2020 | |
| Ucb, INC. | $13.65 | 2019 | |
| Livanova USA, INC. | $12.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tsao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.